Torrent Pharmaceuticals Ltd

Target and business

• Torrent Urja 27 Private Limited, a SPV for captive wind-solar project in Gujarat, India.

Size and financials

• Turnover nil as on 31 March 2026.

Related party and control

• Related party transaction; Torrent Urja is an associate and step-down subsidiary; deal at arm's length.

Industry

• Industry: generation and transmission of hybrid energy (wind, solar, renewables).

Purpose and rationale

• To enhance renewable power share and meet captive-user regulatory requirements.

Approvals

• Regulatory approvals not applicable.

Timeline

• Indicative completion period: 18 to 21 months.

Consideration and stake

• Form of consideration: cash; cost of acquisition: INR 11,87,90,100; 26% stake.

Background of target

• Incorporated in India (Gujarat) on 06-Aug-2024; yet to commence operations.

Torrent Pharmaceuticals Ltd trading window closed from 1st October, 2026; will reopen 48 hours after the submission of the Financial Results for the Quarter ended 30th September, 2026.

Investors Meet – 17 Sep 2026

• 17-Sep-26: Jefferies India Forum 2026, Gurgaon; company representatives to participate in group and one-on-one meetings.

Investors Meet – 18 Sep 2026

• 18-Sep-26: Kotak Healthcare Forum 2026, Mumbai; company representatives to participate in group and one-on-one meetings.

Investors Meet – 21 Sep 2026

• 21-Sep-26: JP Morgan India Conference, Mumbai; company representatives to participate in group and one-on-one meetings.

Resolution No. 1: Appointment of Independent Director (Special)

• Purpose: appoint Shanti Ekambaram as Independent Director.
• Outcome: Passed with 99.98% in favour; 0.02% against.

Meeting Details

• Date: 14-Aug-26; Meeting: Emkay Confluence 2026; Place: Mumbai; Type: Group and one-on-one.

Participants

• Company representatives (management) to participate.

Purpose

• Investor interaction under SEBI LODR regulations.

ESG rating update

• NSE Sustainability Ratings and Analytics Limited assigned Torrent Pharmaceuticals Ltd an ESG rating of 70.
• The update is under SEBI LODR Regulation 30 and related circular requirements.

Meeting Details

• Conference call with analysts/investors on Q1 FY26-27 earnings.
• Transcript available on Torrent Pharmaceuticals website.
• Quarter ended 30 June 2026 referenced.

Appointment of Additional Independent Director

• Shanti Ekambaram appointed as Additional Independent Director for 3-year term, effective 30 July 2026.
• Subject to shareholders' approval; she is not related to any other director.
• Not debarred by SEBI or any authority.